Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica K Altman

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Blood|December 17, 2011
"Boldness be my friend" (Shakespeare; Cymbeline)Jessica K Altman, Martin S Tallman
International Journal of Hematologic Oncology|December 10, 2013
Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathwaysJessica K Altman, Leonidas C Platanias
Hematology. American Society of Hematology. Education Program|December 5, 2025
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?Himachandana Atluri, Yasmin Abaza, Jessica K Altman
Expert Opinion on Investigational Drugs|April 3, 2013
Next generation of mammalian target of rapamycin inhibitors for the treatment of cancerValerie Nelson, Jessica K Altman, Leonidas C Platanias
Oncotarget|June 18, 2011
Targeting mTOR for the treatment of AML. New agents and new directionsJessica K Altman, Antonella Sassano, Leonidas C Platanias
Journal of Cellular Biochemistry|September 20, 2011
Targeting AMPK in the treatment of malignanciesEliza Vakana, Jessica K Altman, Leonidas C Platanias
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapyIrum Khan, Jessica K Altman, Jonathan D Licht
Current Opinion in Hematology|January 15, 2014
New strategies for relapsed acute myeloid leukemia: fertile ground for translational researchShira N Dinner, Francis J Giles, Jessica K Altman
Current Opinion in Oncology|September 6, 2011
Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignanciesNushmia Z Khokhar, Jessica K Altman, Leonidas C Platanias
Leukemia & Lymphoma|January 20, 2016
SNPing away to individualize induction therapy for acute myelogenous leukemiaJason B Kaplan, Jessica K Altman, Leonidas C Platanias
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Blood|December 17, 2011
"Boldness be my friend" (Shakespeare; Cymbeline)Jessica K Altman, Martin S Tallman
International Journal of Hematologic Oncology|December 10, 2013
Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathwaysJessica K Altman, Leonidas C Platanias
Hematology. American Society of Hematology. Education Program|December 5, 2025
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?Himachandana Atluri, Yasmin Abaza, Jessica K Altman
Expert Opinion on Investigational Drugs|April 3, 2013
Next generation of mammalian target of rapamycin inhibitors for the treatment of cancerValerie Nelson, Jessica K Altman, Leonidas C Platanias
Oncotarget|June 18, 2011
Targeting mTOR for the treatment of AML. New agents and new directionsJessica K Altman, Antonella Sassano, Leonidas C Platanias
Journal of Cellular Biochemistry|September 20, 2011
Targeting AMPK in the treatment of malignanciesEliza Vakana, Jessica K Altman, Leonidas C Platanias
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapyIrum Khan, Jessica K Altman, Jonathan D Licht
Current Opinion in Hematology|January 15, 2014
New strategies for relapsed acute myeloid leukemia: fertile ground for translational researchShira N Dinner, Francis J Giles, Jessica K Altman
Current Opinion in Oncology|September 6, 2011
Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignanciesNushmia Z Khokhar, Jessica K Altman, Leonidas C Platanias
Leukemia & Lymphoma|January 20, 2016
SNPing away to individualize induction therapy for acute myelogenous leukemiaJason B Kaplan, Jessica K Altman, Leonidas C Platanias
Pageof 17